High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.
Backed by a former J&J CEO, the startup plans to advance its drug candidates into late-stage trials.
Retirees don’t need the highest yield on the board. They need the check to keep arriving, and to keep growing, through every recession, rate cycle, and regime change. Three Dividend Kings fit that brief: Coca-Cola, Johnson & Johnson, and PepsiCo. Each has raised its payout for decades without a cut, and one benchmark says it […]
Some companies have raised their dividends through recessions, pandemics, wars, and market crashes without missing a single year, and five of them may be the steadiest income plays a retiree can own right now.
Alternative asset manager Apollo Global Management Inc. is in discussions to acquire the Johnson & Johnson orthopedics unit that the conglomerate has been looking to separate, according to people familiar with the matter.
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.
A seven-figure portfolio looks like security until federal taxes, Medicare surcharges, Social Security phase-ins, and inflation each take their share. What actually clears into your checking account from $1.55 million depends on decisions most retirees never see coming.
Treasuries now yield nearly 5%, raising the stakes for every dividend stock in a boomer portfolio. Five companies have raised their payouts through recessions, inflation spikes, and rate cycles, and the case for owning them lifetime has never required more scrutiny.
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.
These stocks can help you withstand (almost) any storm.
For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.
Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.
Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.
Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.
LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for?
Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care. The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75. This year, the newly closed acquisition of Firefly Bio and the ...
AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
